Page 1

BIOSYENT RELEASES Q2 AND H1 2021 FINANCIAL RESULTS ● FOR IMMEDIATE RELEASE MISSISSAUGA , ONTARIO ( August 25 , 2021 ) BioSyent Inc. ( " BioSyent " , TSX Venture : RX ) released today its financial results for the three and six months ended June 30 , 2021. Key highlights include : ● ● ● ● ● ● BioSyent ● ● NEWS RELEASE AUGUST 25 , 2021 Second quarter ( Q2 ) 2021 Net Revenues of $ 7,289,254 increased by 53 % versus Q2 2020 First half ( H1 ) 2021 Net Revenues of $ 14,709,143 increased by 36 % versus H1 2020 Record quarterly Canadian Pharmaceutical Net Revenues in Q2 2021 of $ 6,670,322 increased by 51 % versus Q2 2020 Q2 2021 Net Income After Taxes ( NIAT ) of $ 1,018,074 increased by 41 % versus Q2 2020 H1 2021 NIAT of $ 2,682,442 increased by 23 % versus H1 2020 H1 2021 Canadian Pharmaceutical Net Revenues of $ 12,904,085 increased by 24 % versus H1 2020 Q2 2021 International Pharmaceutical Net Revenues of $ 165,038 increased by 75 % versus Q2 2020 H1 2021 International Pharmaceutical Net Revenues of $ 1,305,317 increased by 705 % versus H1 2020 Q2 2021 EBITDA¹ of $ 1,491,783 increased by 40 % versus Q2 2020 H1 2021 EBITDA¹ of $ 3,850,868 increased by 26 % versus H1 2020 Q2 2021 NIAT percentage to Net Revenues of 14 % compares to 15 % in Q2 2020 H1 2021 NIAT percentage to Net Revenues of 18 % compares to 20 % in H1 2020 Q2 2021 Fully Diluted EPS of $ 0.08 was $ 0.02 higher than Q2 2020 Fully Diluted EPS of $ 0.06 H1 2021 Fully Diluted EPS of $ 0.21 was $ 0.05 higher than H1 2020 Fully Diluted EPS of $ 0.16 Fully Diluted EPS for the Trailing Twelve Months June 30 , 2021 was $ 0.33 as compared to $ 0.36 for the Trailing Twelve Months ended June 30 , 2020 As at June 30 , 2021 , the Company had cash , cash equivalents , and short - term investments totalling $ 24,812,859 , a 3 % decrease as compared to $ 25,577,706 as at December 31 , 2020 Total Shareholders ' Equity increased by 7 % to $ 28,805,167 at June 30 , 2021 from $ 26,795,956 at December 31 , 2020 Return on Equity for the Trailing Twelve Months ended June 30 , 2021 was 16 % as compared to 20 % for the Trailing Twelve Months ended June 30 , 2020 During H1 2021 , repurchased and cancelled a total of 74,500 common shares under a Normal Course Issuer Bid ( NCIB ) " Our established brands , led by FeraMAX® , showed strength and resilience through the challenges of COVID - 19 resulting in 51 % growth in Canadian pharmaceutical sales in Q2 2021 as compared to a 9 % decline in the year ago period , which was impacted by short - term trade inventory rebalancing coming out of the first wave of COVID - 19 , " commented Mr. René Goehrum , President and CEO of BioSyent . " Bolstered by growth in our legacy and international pharmaceutical businesses , total Company sales grew by 53 % to $ 7.3 million in Q2 2021. While our launch brands , Tibella® and Combogesic® , contributed to growth during the quarter , COVID - 19 - related access restrictions to healthcare professionals and persistently low patient traffic through the offices of these healthcare professionals have delayed the expected rate of uptake of these two brands . Although we are encouraged by the lifting of some COVID - 19 - related restrictions across Canada , the future impact of COVID - 19 on the launch trajectory of these two brands remains uncertain . While we continued